EGFR and non-small cell lung carcinoma: The findings made in this study provide theoretical support for subsequent treatment strategies for NSCLC patients exhibiting EGFR‐TKIs resistance, emphasizing the importance of comprehensive genetic profiling in therapeutic decision‐making.